Cancer Research

Early Data Presented At ASCO Show Potential Of RAD001 To Enhance Efficacy Of, And Overcome Resistance To, Breast Cancer Treatmen

FRIMLEY, England, June 2 /PRNewswire/--- Randomised Phase II data show RAD001 significantly increased efficacy of letrozole in women with newly diagnosed hormone-positive breast cancer- Phase I studies suggest RAD001 may help overcome a major pathway of r ...

Article - Anna Ohlden - Jun 2 2008 - 3:32am

Roche Signs Exclusive Distribution Deal With DxS For K-RAS And EGFR Cancer Mutation Tests

PLEASANTON, California, June 2 /PRNewswire/--- Tests identify genetic mutations that can affect patient response to certain cancer drugs Roche and DxS Ltd. have signed an exclusive distribution agreement for the DxS TheraScreen K-RAS Mutation Test and The ...

Article - Anna Ohlden - Jun 2 2008 - 5:33am

ThromboGenics And BioInvent Report Positive Phase I Results For Anti-PlGF Cancer Therapeutic TB-403

LEUVEN, Belgium and LUND, Sweden, June 3 /PRNewswire/--- Approval Also Received to Start Second Repeat-Dose Phase I Study in Patients With Advanced Cancer ThromboGenics NV (Euronext Brussels: THR) and co-development partner BioInvent International AB (Nor ...

Article - Anna Ohlden - Jun 3 2008 - 1:32am

Gen-Probe Launches Cash Tender Offer To Acquire Belgian Molecular Diagnostics Company Innogenetics

SAN DIEGO, June 3 /PRNewswire/--- Acquisition Expected to Accelerate Gen-Probe's Commercial Expansion in Fast-Growing European Market; Add Complementary Products, Technologies and Markers-- Combined Entity Anticipated to be World's Largest Stand ...

Article - Anna Ohlden - Jun 3 2008 - 7:33am

Retaining Employees' Capacity For Work Following Sickness

BERLIN, June 4 /PRNewswire/--- The 4th International Forum on Disability Management Will be Held in Berlin from 22 to 24 September. How can businesses retain employees' capacity for work following sickness and disablement? Experts from throughout the ...

Article - Anna Ohlden - Jun 4 2008 - 3:32am

A New Molecular Mechanism For Colorectal Cancer: A New Target For Cancer Therapies

Scientists in Portugal just found a new molecular mechanism behind colorectal cancer in which a mutated and a normal, but over-expressed, gene cooperate and are both needed to create the disease. The research, published in the journal Gastroenteroloy1, als ...

Article - Catarina Amorim - Sep 19 2008 - 4:54pm

Synthetic Molecules Reduce Human Malignant Tissues In Mice

Synthetic molecules designed by two Hebrew University of Jerusalem researchers have succeeded in reducing and even eliminating the growth of human malignant tissues in mice, while having no toxic effects on normal tissue. The molecules developed by Dr. Ari ...

Article - News Staff - Jun 4 2008 - 5:02pm

Unintended Consequence- Kylie Minogue's Breast Cancer Boosted Unnecessary Biopsies

Kylie Minogue's breast cancer triggered a surge of over 30 percent in breast imaging of low risk women, says new University of Melbourne study. Use of mammography and breast ultrasound procedures soared among women aged 25-44 in the six months followi ...

Article - News Staff - Jun 4 2008 - 11:56pm

Merck Serono Announces Initiation Of Second Phase II/III Clinical Study Of Atacicept In Lupus

GENEVA, Switzerland, June 5 /PRNewswire/--- Trial in Systemic Lupus Erythematosus (SLE) Intended to Form Part of Potential Registration Package Merck Serono, a division of Merck KGaA, Darmstadt, Germany, and its development partner ZymoGenetics, Inc. (NAS ...

Article - Anna Ohlden - Jun 5 2008 - 1:32am

SemBioSys Demonstrates Functionality Of Its Safflower Produced Apo AI(Milano)

CALGARY, Canada, June 5 /PRNewswire/--- Company Achieves Important Milestone in Development of Next Generation Cardiovascular Drug ...

Article - Anna Ohlden - Jun 5 2008 - 6:30am